Rivaroxaban para el tratamiento de la trombocitopenia inducida por heparina: caso clínico / Treatment of heparin-induced thrombocytopenia with rivaroxaban: case report
Rev. méd. Chile
;
145(9): 1213-1217, set. 2017. tab, graf
Article
in Spanish
| LILACS
| ID: biblio-902610
ABSTRACT
Heparin-induced thrombocytopenia (HIT) is immune-mediated. It occurs more frequently with unfractionated heparin (UFH) than with low molecular weight heparins (LMWH). It is associated with thromboembolic rather than hemorrhagic events, as opposed to thrombocytopenia of other etiologies. The key in therapy is the cessation of heparin and the start of another anticoagulant. We report a 58 years old female with HIT secondary to the use of Enoxaparin who was successfully managed with Rivaroxaban. Our goal is to report a novel therapy and provide the evidence that supports its use.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Thrombocytopenia
/
Heparin
/
Factor Xa Inhibitors
/
Rivaroxaban
/
Anticoagulants
Type of study:
Etiology study
/
Risk factors
Limits:
Female
/
Humans
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2017
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Pontificia Universidad Católica de Chile/CL
Similar
MEDLINE
...
LILACS
LIS